The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents

Benjamin, 2017, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, heart disease and stroke statistics-2017 update: a report from the American Heart Association, Circulation, 135, e146, 10.1161/CIR.0000000000000485 Alfonso, 2014, Current treatment of in-stent restenosis, J. Am. Coll. Cardiol., 63, 2659, 10.1016/j.jacc.2014.02.545 Byrne, 2015, Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014, Eur. Heart J., 36, 3320, 10.1093/eurheartj/ehv511 Fukuhara, 2005, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin, Science, 307, 426, 10.1126/science.1097243 Romacho, 2013, Visfatin as a novel mediator released by inflamed human endothelial cells, PLoS One, 8, 10.1371/journal.pone.0078283 Kadoglou, 2011, Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study, Clin. Chim. Acta, 412, 48, 10.1016/j.cca.2010.09.012 Dahl, 2007, Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization, Circulation, 115, 972, 10.1161/CIRCULATIONAHA.106.665893 Lu, 2012, Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction, Cytokine, 57, 74, 10.1016/j.cyto.2011.10.015 Chen, 2017, Nicotinamide phosphoribosyltransferase promotes pulmonary vascular remodeling and is a therapeutic target in pulmonary arterial hypertension, Circulation, 135, 1532, 10.1161/CIRCULATIONAHA.116.024557 Kadoglou, 2014, Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis, Peptides, 57, 12, 10.1016/j.peptides.2014.04.008 Pitoulias, 2017, The role of visfatin in atherosclerotic peripheral arterial obstructive disease, Cytokine, 91, 140, 10.1016/j.cyto.2016.12.027 Serruys, 2006, Coronary-artery stents, N. Engl. J. Med., 354, 483, 10.1056/NEJMra051091 Otsuka, 2012, The importance of the endothelium in atherothrombosis and coronary stenting, Nat. Rev. Cardiol., 9, 439, 10.1038/nrcardio.2012.64 Moschen, 2007, Visfatin, an adipocytokine with proinflammatory and immunomodulating properties, J. Immunol., 178, 1748, 10.4049/jimmunol.178.3.1748 Luk, 2008, Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity, J. Leukoc. Biol., 83, 804, 10.1189/jlb.0807581 van der Veer, 2005, Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation, Circ. Res., 97, 25, 10.1161/01.RES.0000173298.38808.27 Anfossi, 2010, Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells, Mediat. Inflamm., 2010, 174341, 10.1155/2010/174341 Wang, 2016, NAMPT and NAMPT-controlled NAD metabolism in vascular repair, J. Cardiovasc. Pharmacol., 67, 474, 10.1097/FJC.0000000000000332 Yang, 2013, Changes and significance of serum visfatin before and after coronary stent implantation in patients with coronary heart disease, J. China Med. Univ., 42, 214 Inoue, 2011, Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis, JACC Cardiovasc. Interv., 4, 1057, 10.1016/j.jcin.2011.05.025